用地塞米松做雾化,合理吗 ?

2016-07-20 佚名 医学之声

临床上有很多使用地塞米松作为雾化用药,那么它真的适合雾化吗?今天小编一起来和大家讨论这个问题。雾化吸入是我们临床常用的一种给药方式,特别是呼吸内科,其优点就是用较少剂量的药物,直接作用于气道或者肺部。这样起效也相对较快,副作用也相对静脉给药少,在我们临床上有很多使用地塞米松作为雾化用药,那么它真的适合雾化吗?今天小编一起来和大家讨论这个问题。激素雾化吸入目的就在于减少全身的副作用,同时直接作用于病

临床上有很多使用地塞米松作为雾化用药,那么它真的适合雾化吗?今天小编一起来和大家讨论这个问题。

雾化吸入是我们临床常用的一种给药方式,特别是呼吸内科,其优点就是用较少剂量的药物,直接作用于气道或者肺部。这样起效也相对较快,副作用也相对静脉给药少,在我们临床上有很多使用地塞米松作为雾化用药,那么它真的适合雾化吗?今天小编一起来和大家讨论这个问题。

激素雾化吸入目的就在于减少全身的副作用,同时直接作用于病灶,效果快而显著。但是地米却不具备这种优势,所以地米不推荐作为雾化药物使用。这是因为

1、地塞米松经呼吸道局部雾化吸入时,产生的雾化颗粒较大,达不到3~5μm的有效颗粒,因而药物只能沉积在大气道。

2、由于地米结构中无亲脂性基团,因而与糖皮质激素受体的亲和力较低,局部抗炎作用弱。其水溶性较大,与大气道粘膜组织结合较少,肺内沉积率低。

3、地塞米松需在肝脏转化后才起作用,因此很难在局部直接产生疗效。

4、地米是糖皮质激素的长效制剂,起效慢,全身作用广,相对的副作用也大。

5、地米的生物半衰期较长,在体内容易蓄积,对丘脑下部-垂体-肾上腺轴的抑制作用也增强。

综合上述地塞米松雾化所希望达到的局部用药的意义,跟全身用药没什么两样,反而增加了雾化的费用,地米雾化吸入后血液浓度大于局部浓度。

目前国内有糖皮质激素雾化吸入剂型:吸入用布地奈德混悬液。用法和用量:一次1~2mg,一日2次。雾化吸入布地奈德起效迅速,10~30分钟即可发挥气道抗炎作用。

其不良反应

声嘶、溃疡、咽部疼痛不适、舌部和口腔刺激、口干、咳嗽和口腔念珠菌病。如果发现口咽念珠菌病,可用适当的抗真菌药治疗,并继续使用布地奈德。让患者在每次吸入后漱口,可使念珠菌感染的发生率减至最低。通常患者对布地奈德的耐受性较好。大多数不良反应都很轻微,且为局部性。布地奈德引起的全身作用和口咽并发症与剂量有关。每日1.6mg或更大剂量布地奈德且长期单独使用的患者中,有50%的患者出现类固醇过量的临床表现。

注意事项

①单独应用布地奈德雾化吸入不能快速缓解气流受限。因此布地奈德不宜单独用于治疗AECOPD,需与支气管舒张剂等药物联合使用。

②布地奈德雾化吸入可能会掩盖一些已有感染的症状,也可能在使用时诱发新的感染。对患有活动或静止期肺结核病的患者或呼吸系统的真菌、细菌或病毒感染者需慎用。

原始出处


冯玉麟.成人慢性气道疾病雾化吸入治疗专家共识[J].中国呼吸与危重监护杂志,2012,11(2):105-110.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=94819, encodeId=6d13948196c, content=学习了,点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 27 07:11:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457720, encodeId=05d0145e7203e, content=<a href='/topic/show?id=e2d1988611e' target=_blank style='color:#2F92EE;'>#雾化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98861, encryptionId=e2d1988611e, topicName=雾化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Jul 22 05:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94028, encodeId=81cc94028af, content=学习学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 21 11:31:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93924, encodeId=ad1e939245e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93925, encodeId=5c2a93925ab, content=值得去阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93923, encodeId=d0d59392325, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:32:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2016-07-27 yde2801fm***3926(暂无匿称)

    学习了,点赞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=94819, encodeId=6d13948196c, content=学习了,点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 27 07:11:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457720, encodeId=05d0145e7203e, content=<a href='/topic/show?id=e2d1988611e' target=_blank style='color:#2F92EE;'>#雾化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98861, encryptionId=e2d1988611e, topicName=雾化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Jul 22 05:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94028, encodeId=81cc94028af, content=学习学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 21 11:31:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93924, encodeId=ad1e939245e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93925, encodeId=5c2a93925ab, content=值得去阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93923, encodeId=d0d59392325, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:32:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=94819, encodeId=6d13948196c, content=学习了,点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 27 07:11:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457720, encodeId=05d0145e7203e, content=<a href='/topic/show?id=e2d1988611e' target=_blank style='color:#2F92EE;'>#雾化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98861, encryptionId=e2d1988611e, topicName=雾化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Jul 22 05:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94028, encodeId=81cc94028af, content=学习学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 21 11:31:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93924, encodeId=ad1e939245e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93925, encodeId=5c2a93925ab, content=值得去阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93923, encodeId=d0d59392325, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:32:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2016-07-21 1dd8c52fm63(暂无匿称)

    学习学习!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=94819, encodeId=6d13948196c, content=学习了,点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 27 07:11:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457720, encodeId=05d0145e7203e, content=<a href='/topic/show?id=e2d1988611e' target=_blank style='color:#2F92EE;'>#雾化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98861, encryptionId=e2d1988611e, topicName=雾化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Jul 22 05:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94028, encodeId=81cc94028af, content=学习学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 21 11:31:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93924, encodeId=ad1e939245e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93925, encodeId=5c2a93925ab, content=值得去阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93923, encodeId=d0d59392325, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:32:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2016-07-20 doctorJiangchao

    继续努力

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=94819, encodeId=6d13948196c, content=学习了,点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 27 07:11:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457720, encodeId=05d0145e7203e, content=<a href='/topic/show?id=e2d1988611e' target=_blank style='color:#2F92EE;'>#雾化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98861, encryptionId=e2d1988611e, topicName=雾化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Jul 22 05:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94028, encodeId=81cc94028af, content=学习学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 21 11:31:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93924, encodeId=ad1e939245e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93925, encodeId=5c2a93925ab, content=值得去阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93923, encodeId=d0d59392325, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:32:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2016-07-20 doctorJiangchao

    值得去阅读

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=94819, encodeId=6d13948196c, content=学习了,点赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Wed Jul 27 07:11:00 CST 2016, time=2016-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457720, encodeId=05d0145e7203e, content=<a href='/topic/show?id=e2d1988611e' target=_blank style='color:#2F92EE;'>#雾化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98861, encryptionId=e2d1988611e, topicName=雾化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Fri Jul 22 05:17:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94028, encodeId=81cc94028af, content=学习学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Jul 21 11:31:00 CST 2016, time=2016-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93924, encodeId=ad1e939245e, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93925, encodeId=5c2a93925ab, content=值得去阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:33:00 CST 2016, time=2016-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93923, encodeId=d0d59392325, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Wed Jul 20 19:32:00 CST 2016, time=2016-07-20, status=1, ipAttribution=)]
    2016-07-20 doctorJiangchao

    继续关注

    0

相关资讯

WCIO:地塞米松和福沙吡坦可以降低DEB TACE术后PES风险

根据介入肿瘤学世界会议的报告,对原发性肝癌(HCC)患者进行药物洗脱珠肝动脉化疗栓塞术 (DEB TACE) 前联合使用Decadron和Emend,可以预防患者治疗后的栓塞后综合征。辛辛那提大学介入放射学助理教授Abouelmagd Makramalla博士和同事对71名进行DEB TAC的HCC患者进行了研究。一共涉及113个操作,所有患者在术前通过静脉注射8 mg of Decadron(地

Lancet Oncol:地塞米松可减少治疗中辐射引起的疼痛耀斑

疼痛耀斑常发生在姑息性放疗后,地塞米松已经显示出预防此类耀斑的潜力。该研究的目的是比较地塞米松与安慰剂相比,对于减少疼痛耀斑的功效比较。在这项双盲,随机,安慰剂对照的Ⅲ期试验中,来自23个加拿大中心的患者通过一个基于网络的系统和最小化算法被随机分配(1:1),接受口服两次4毫克地塞米松片或每天两次安慰剂片,在放射治疗前至少1小时口服(针对骨转移一个8 Gy剂量;第0天),然后放疗后进行4天进行口服

NEJM:地塞米松不能够降低HIV感染相关的隐球菌性脑膜炎死亡率

人类免疫缺陷病毒(HIV)感染相关的隐球菌性脑膜炎每年导致全球超过60万人死亡。治疗20年变化不大,且没有新的抗隐球菌剂。使用辅助糖皮质激素可降低某些人群脑膜炎患者的死亡率,但其在隐球菌性脑膜炎患者中的使用未经测试。在这项双盲,随机,安慰剂对照试验中,研究人员在越南,泰国,印度尼西亚,老挝,乌干达,马拉维招募了HIV相关隐球菌性脑膜炎成年患者。所有的患者接受了6周地塞米松或安慰剂,并结合抗真菌治疗

Pediatrics:抗生素+地塞米松治疗化脓性关节炎更有效

有前瞻性研究表明,对化脓性关节炎儿童在抗生素治疗同时添加地塞米松可以显著改善患者的临床表现和实验室检查结果。研究者进行了一项随机对照试验探究地塞米松对儿童化脓性关节炎的有效性。该研究于2008-2013年间在三级儿科中心收集化脓性关节炎住院的患者相关信息。比较单独使用抗生素和抗生素+地塞米松两组的疗效。最终研究纳入了116名患者,90名为抗生素组(对照组),26名为抗生素+地塞米松组(实验组)。实

Reg Anesth Pain Med:围术期地塞米松的使用不能改善乳癌患者的术后疼痛

研究人员猜测,手术相关炎症反应的围术期调节,可作为术后疼痛的一个可行的药理学防治指标。本次研究旨在评价手术当天静脉注射4-20mg地塞米松,与乳房切除术后至少3个月患者自述乳房或腋下疼痛的相关性。   本次研究为一项前瞻性群组研究的二次资料分析。使用验证疼痛问卷对进行乳房切除术后至少3个月的患者的慢性术后疼痛进行评价。使用二元逻辑回归分析,对接受及未接受围术期地塞米松治疗患者的慢性术

NEJM:口服Ixazomib、来那度胺、地塞米松治疗可显著延长多发性骨髓瘤患者的无进展生存期(TOURMALINE-MM1研究)

ixazomib是一种口服的蛋白酶体抑制剂,目前正在研究用于治疗多发性骨髓瘤。原始出处:Philippe Moreau,Tamás Masszi,Norbert Grzasko,et al.Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,NEJM,2016.4.28http://www.nejm.org/doi